


FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. TOYAM77.001AUS	APPLICATION NO. 09/883,316
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Toshio Imai, et al.	
		FILING DATE September 25, 2001	GROUP Unknown

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	FILING DATE (IF APPROPRIATE)

FOREIGN PATENT DOCUMENTS								
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
R✓	1.	2001-218581	08/14/01	Japan (Concise explanation of he relevance)	—	—	abstract	

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
R✓	2.	Toshio Imai, et al., Identification and Molecular Characterization of Fractalkine Receptor CX <sub>3</sub> CR1, which Mediates Both Leukocyte Migration and Adhesion, Cell, Vol. 91, 521-530, November 14, 1997
I	3.	Lili Feng, et al., Prevention of crescentic glomerulonephritis by immunoneutralization of the fractalkine receptor CX <sub>3</sub> CR1 <i>Rapid Communication</i>
	4.	Proceedings of the Japanese Society for Immunology, Vol. 30, 2000, p.192; 2-F-270-P/O with an English translation

H:\DOCS\KOA\KOA-2383.DOC  
040502

EXAMINER		DATE CONSIDERED	2/17/04
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.			